<DOC>
	<DOC>NCT01471171</DOC>
	<brief_summary>The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg twice a day (BID) administered twice a day versus placebo on exercise endurance and on hyperinflation and dyspnoea at rest and during exercise after 3 weeks of treatment.</brief_summary>
	<brief_title>Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Adult male and female patients aged ≥ 40 with stable moderate to severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines). Postsalbutamol Forced Expiratory Volume in one second(FEV1) &lt; 80% and ≥ 30% of predicted normal value and Postsalbutamol FEV1/Forced Vital Capacity (FVC) &lt; 70%. Current or exsmokers of ≥ 10 packyears Functional residual capacity (FRC) measured by body plethysmography at Screening Visit ≥ 120% of predicted value History or current diagnosis of asthma Signs of an exacerbation within 6 weeks ( or 3 months if results in hospitalisation) prior to the screening visit or during the runin period. Clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities. Conditions where the use of anticholinergic drugs is contraindicated, such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrowangle glaucoma. Patients with an oxygen saturation &lt; 85% during cycle exercise on room air at Screening Visit, Run in Visit and Visit 1. Contraindications of cardiopulmonary exercise testing. Patient who in the investigator's opinion will need to start a pulmonary rehabilitation program during the study and/or patients who have just started/finished pulmonary rehabilitation at least 3 months prior to the Screening Visit.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Antimuscarinic</keyword>
</DOC>